MetaCap

Annovis Bio (ANVS) vs Spero Therapeutics (SPRO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Spero Therapeutics (SPRO) has outperformed Annovis Bio (ANVS) over the past year, losing 67.9% versus a loss of 81.2%. Over five years, SPRO leads with a -95.1% price change compared with -97.2% for ANVS. Annovis Bio is the larger company by market cap ($44.1 million vs $43.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ANVS-81.23%SPRO-67.88%
+40%-24%-88%
Nov 21, 20251 yearNov 20, 2026
ANVS-97.38%SPRO-95.50%
+5%-49%-102%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ANVS versus SPRO key metrics
MetricANVSSPRO
Share price$0.7113$0.742
Market cap$44.12M$43.23M
1-day change-4.96%-10.20%
YTD return-79.44%-68.15%
1-year return-81.23%-67.88%
5-year return-97.24%-95.09%
EPS (TTM)$-1.55$-0.50
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$66.80M
Revenue growth (YoY)—+39.24%
Net income (latest FY)$-28.85M$8.57M
Operating margin—9.45%
Net margin—12.83%
52-week high$5.50$3.08
52-week low$0.62$0.73
Distance from 52-week high-87.07%-75.91%
Analyst consensusnonenone
Avg. price target upside+1376.17%+573.85%
Average volume1.82M530.46K
Shares outstanding62.02M58.26M
Employees725
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SPRO has outperformed ANVS by 13.4 percentage points over the past year.

About Annovis Bio

ANVS stock →

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

About Spero Therapeutics

SPRO stock →

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial.

Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees

ANVS vs SPRO FAQ

Which is bigger, Annovis Bio or Spero Therapeutics?

Annovis Bio (ANVS) is larger, with a market capitalization of $44.12M compared with $43.23M for Spero Therapeutics (SPRO).

Which stock has performed better over the past year, ANVS or SPRO?

SPRO returned -67.88% over the past 12 months, compared with -81.23% for ANVS (price return, excluding dividends). Past performance does not predict future results.

Are Annovis Bio and Spero Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons